4 reports

  • 9.2.2.3. CAR-T THERAPY AND RESEARCH LANDSCAPE
  • IN DEVELOPING CAR-T THERAPIES; ACADEMIC INSTITUTES CONTINUE TO MAKE SIGNIFICANT CONTRIBUTIONS TO THE INNOVATION IN THIS DOMAIN

INTRODUCTION Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of...

  • Automotive
  • Clinical Trial
  • Motor Vehicle
  • Therapy
  • Kite Pharma, Inc.

ONE STEP FORWARD IN THIS DIRECTION WAS THE FIRST HUMAN TRIAL OF AN ANTI-BCMA CAR-T THERAPY.

  • Automotive
  • Motor Vehicle
  • Targeted Therapy
  • Therapy
  • Kite Pharma, Inc.
  • KITE PHARMA: CAR-T PIPELINE
  • THERAPIES

INTRODUCTION The human immune system is comprised of a number of different types of specialized molecules and cells that are involved in complex interactions and activities to facilitate an immune response. Immunotherapies exploit the body's innate potential to specifically target a particular molecular antigen and mount an efficient...

  • Automotive
  • Monoclonal Antibody
  • Therapy
  • United States
  • Kite Pharma, Inc.
  • CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY

CLINICAL TRIAL RESULTS FOR CD## CAR, KTE-C## CAR, EGFRVIII CAR, NY-ESO-## TCR AND MAGE A##/ A## TCR HAVE BEEN DISCUSSED EARLIER IN CHAPTER ## AND ##.

  • Automotive
  • Cell Therapy
  • Motor Vehicle
  • Therapy
  • Kite Pharma, Inc.